Patent Issued for Anti-TMPRSS2 antibodies and antigen-binding fragments (USPTO 11999799).

Regeneron Pharmaceuticals Inc. has been granted a patent for anti-TMPRSS2 antibodies and antigen-binding fragments. The patent highlights the need for new antiviral strategies in response to drug resistance and emerging viruses. The invention offers therapeutic antibodies that specifically target human TMPRSS2, a protein involved in the activation of respiratory viruses like influenza and coronaviruses. These antibodies have potential applications in the treatment of viral infections. The patent provides comprehensive information on the amino acid sequences and characteristics of the antibodies, making it a valuable resource for researchers interested in studying or developing these antibodies. [Extracted from the article]